Dallas' Lantern Pharma Focuses on Fighting Lung Cancer for Non-Smokers

Lung cancer patients often face stigma due to the disease's link with smoking, leading to less support and funding compared to other cancers—even though it’s the top cancer killer in the U.S. This stigma especially affects the 15-25% of patients who have never smoked. As smoking's health risks became widely known, lung cancer cases among never-smokers increased, notably among certain groups. For instance, studies show 57% of Asian women with lung cancer in California and a third in East Asia are non-smokers. Yet, screenings and insurance coverage for non-smokers are more complicated, and no treatment specifically targets them.

Dallas-based Lantern Pharma has reported promising results for non-smoking patients with advanced non-small cell lung cancer. Their Phase 2 trial, focused on AI-driven treatments, showed an 86% clinical benefit and a 43% objective response rate, with no safety issues.

Learn more